Search

Your search keyword '"Castelletti, N"' showing total 3 results
Start Over Author "Castelletti, N" Topic vaccination
3 results on '"Castelletti, N"'

1. Understanding the Omicron Variant Impact in Healthcare Workers: Insights from the Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf) on Risk Factors for Breakthrough and Reinfections.

Author

Janke C, Rubio-Acero R, Weigert M, Reinkemeyer C, Khazaei Y, Kleinlein L, Le Gleut R, Radon K, Hannes M, Picasso F, Lucke AE, Plank M, Kotta IC, Paunovic I, Zhelyazkova A, Noreña I, Winter S, Hoelscher M, Wieser A, Küchenhoff H, Castelletti N, and On Behalf Of The Orchestra Working Group

Subjects
Humans, Adult, Male, Female, Middle Aged, Risk Factors, Germany epidemiology, Prospective Studies, Seroepidemiologic Studies, Young Adult, Aged, Adolescent, Breakthrough Infections, COVID-19 immunology, COVID-19 epidemiology, SARS-CoV-2 immunology, Health Personnel, Antibodies, Viral blood, Antibodies, Viral immunology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Reinfection immunology, Reinfection epidemiology, Reinfection virology, Vaccination
Abstract

This study analyzes immune responses to SARS-CoV-2 vaccination and infection, including asymptomatic cases, focusing on infection risks during the Omicron wave, particularly among high-risk healthcare workers. In the KoCo-Impf study, we monitored 6088 vaccinated participants in Munich aged 18 and above. From 13 May to 31 July 2022, 2351 participants were follow-uped. Logistic regression models evaluated primary, secondary, and breakthrough infections (BTIs). Roche Elecsys ® Anti-SARS-CoV-2 assays detected prior infections (via anti-Nucleocapsid antibodies) and assessed vaccination/infection impact (via anti-Spike antibodies) using dried blood spots. Our findings revealed an anti-Nucleocapsid seroprevalence of 44.1%. BTIs occurred in 38.8% of participants, with reinfections in 48.0%. Follow-up participation was inversely associated with current smoking and non-vaccination, while significantly increasing with age and receipt of three vaccine doses. Larger household sizes and younger age increased infection risks, whereas multiple vaccinations and older age reduced them. Household size and specific institutional subgroups were risk factors for BTIs. The anti-Nucleocapsid value prior to the second infection was significantly associated with reinfection risk. Institutional subgroups influenced all models, underscoring the importance of tailored outbreak responses. The KoCo-Impf study underscores the importance of vaccination, demographic factors, and institutional settings in understanding SARS-CoV-2 infection risks during the Omicron wave.

Published
2024
Full Text
View/download PDF

2. A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay

Author

Beyerl, J., Rubio-Acero, R., Castelletti, N., Paunovic, I., Kroidl, I., Khan, Z.N., Bakuli, A., Tautz, A., Oft, J., Hoelscher, M., Wieser, A., KoCo19 Study group (Fuchs, C.), and KoCo19 Study group (Le Gleut, R.)

Subjects
medicine.medical_specialty, Medicine (General), Antibody, Covid-19, Dbs, Dried Blood Spot, Filter Paper, Nucleocapsid, Roche Elecsys, Sars-cov-2, Serology, Population, DBS, Dried blood spot, Antibodies, Viral, Filter paper, Sensitivity and Specificity, General Biochemistry, Genetics and Molecular Biology, COVID-19 Serological Testing, Specimen Handling, Cohort Studies, R5-920, medicine, Humans, Sampling (medicine), Longitudinal Studies, education, Asymptomatic Infections, Protocol (science), education.field_of_study, business.industry, SARS-CoV-2, Vaccination, COVID-19, General Medicine, Cohort, Emergency medicine, Medicine, Biological Assay, Dried Blood Spot Testing, business, Blood drawing, Cohort study, Research Paper
Abstract

Background Since 2020 SARS-CoV-2 spreads pandemically, infecting more than 119 million people, causing >2·6 million fatalities. Symptoms of SARS-CoV-2 infection vary greatly, ranging from asymptomatic to fatal. Different populations react differently to the disease, making it very hard to track the spread of the infection in a population. Measuring specific anti-SARS-CoV-2 antibodies is an important tool to assess the spread of the infection or successful vaccinations. To achieve sufficient sample numbers, alternatives to venous blood sampling are needed not requiring medical personnel or cold-chains. Dried-blood-spots (DBS) on filter-cards have been used for different studies, but not routinely for serology. Methods We developed a semi-automated protocol using self-sampled DBS for SARS-CoV-2 serology. It was validated in a cohort of matched DBS and venous-blood samples (n = 1710). Feasibility is demonstrated with two large serosurveys with 10247 company employees and a population cohort of 4465 participants. Findings Sensitivity and specificity reached 99·20% and 98·65%, respectively. Providing written instructions and video tutorials, 99·87% (4465/4471) of the unsupervised home sampling DBS cards could be analysed. Interpretation DBS-sampling is a valid and highly reliable tool for large scale serosurveys. We demonstrate feasibility and accuracy with a large validation cohort including unsupervised home sampling. This protocol might be of big importance for surveillance in resource-limited settings, providing low-cost highly accurate serology data. Funding Provided by Bavarian State Ministry of Science and the Arts, LMU University-Hospital; Helmholtz-Centre-Munich, German Ministry for Education and Research (project01KI20271); University of Bonn; University of Bielefeld; the Medical Biodefense Research Program of Bundeswehr-Medical-Service; Euroimmun, RocheDiagnostics provided discounted kits and machines

Published
2021

3. Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers - ORCHESTRA project

Author

Collatuzzo, Giulia, Visci, Giovanni, Violante, Francesco S, Porru, Stefano, Spiteri, Gianluca, Monaco, Maria Grazia Lourdes, Larese Fillon, Francesca, Negro, Corrado, Janke, Christian, Castelletti, Noemi, De Palma, Giuseppe, Sansone, Emanuele, Mates, Dana, Teodorescu, Silvia, Fabiánová, Eleonóra, Bérešová, Jana, Vimercati, Luigi, Tafuri, Silvio, Abedini, Mahsa, Ditano, Giorgia, Asafo, Shuffield S, Boffetta, Paolo, Zunarelli, Carlotta, Bonfiglioli, Roberta, Carta, Angela, Verlato, Giuseppe, Lippi, Giuseppe, Gibellini, Davide, Pezzani, Maria Diletta, Torroni, Lorena, Hoelscher, Michael, Wieser, Andreas, Reinkemeyer, Christina, Plank, Michael, Noreña, Ivan, Rubio-Acero, Raquel, Winter, Simon, Leustean, Mihaela, Perseca, Ovidiu, Ipate, Madalina, Agripina, Rascu, Strhársky, Jozef, Hellebrandt, Petra, Križanová, Daniela, Mrázová, Marianna, De Maria, Luigi, Sponselli, Stefania, Stefanizzi, Pasquale, Caputi, Antonio, Collatuzzo G., Visci G., Violante F.S., Porru S., Spiteri G., Monaco M.G.L., Larese Fillon F., Negro C., Janke C., Castelletti N., De Palma G., Sansone E., Mates D., Teodorescu S., Fabianova E., Beresova J., Vimercati L., Tafuri S., Abedini M., Ditano G., Asafo S.S., and Boffetta P.

Subjects
COVID-19 Vaccines, vaccine, COVID – 19, serology, health care workers (HCW), immune response, Health Personnel, Immunology, COVID – 19, Vaccination, health care workers (HCW), Immunity, immune response, serology, vaccine, Infant, COVID-19, Antibodies, Viral, Antibodies, Immunoglobulin G, Immunology and Allergy, Humans, Female, Viral, Human
Abstract

BackgroundThe duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs).MethodsWe analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1st dose and serology ranged 150-210 days. Serological levels were log-transformed to account for the skewness of the distribution and normalized by dividing them by center-specific standard errors, obtaining standardized values. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of 1 standard deviation of log antibody level and corresponding 95% confidence interval (CI), and finally combined them in random-effects meta-analyses.ResultsA 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (pConclusionsFemale gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results